Endo updates guidance after Q3 results

• Endo International (NASDAQ:ENDP -3.1%) Q3 results: Revenues: $763.9M (+15.5%); COGS: $379.2M (+47.1%); R&D Expense: $30.9M (-15.8%); SG&A: $205.2M (+7.2%); Operating Loss: ($331.7M) (-333.3%); Net Loss: ($252.1M) (-727.1%); Loss Per Share: ($1.64) (-597.0%); Quick Assets: $713.9M (+35.6%); CF Ops: $232.2M (-14.8%).
• 2014 Guidance: Total revenue: $2.80B - 2.88B from $2.78B - 2.86B; GAAP loss/share: ($3.95 - 3.80) from ($1.56 - 1.36); non-GAAP EPS: $4.10 - 4.25 from $4.00 - 4.20.